Systemic Light Chain Amyloidosis Clinical Trials
3 recruiting trials for Systemic Light Chain Amyloidosis. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Systemic Light Chain Amyloidosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 33% (1 studies); the largest phase groups are Phase 2: 1, Phase 1 / Phase 2: 1, Early Phase 1: 1.
Research is led by Institute of Hematology & Blood Diseases Hospital, China (1), Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1), Beijing Boren Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is anti-BCMA/CD3 bispecific antibody (drug, 1 trial), followed by TQB2934 injection, Targeted BCMA Autologous CART Cell Injection.
Track Systemic Light Chain Amyloidosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly...
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain...
This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the...
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Systemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations and difficulties in diagnosis and...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Systemic Light Chain Amyloidosis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Systemic Light Chain Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Systemic Light Chain Amyloidosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.